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Background: For the last decade, the Cox maze III procedure has been available for
the treatment of atrial fibrillation. It is unknown whether the operation has similar
efficacy in patients with lone atrial fibrillation compared with that in patients with
atrial fibrillation associated with coronary, valve, or congenital heart disease. This
study examined the long-term outcome of patients who underwent this procedure
either as a lone operation or as a concomitant procedure.
Methods: From 1988 to 2001, 198 patients underwent a Cox maze III procedure;
112 were lone operations, and 86 were concomitant procedures. Major complica-
tions included renal failure, reoperation for bleeding, mediastinitis, stroke, and
balloon pump insertion. Follow-up was performed by means of mail and telephone
questionnaires with both the patients and their cardiologists. All patients who had
any history of arrhythmia or who were taking medication had their rhythm docu-
mented by means of electrocardiography.
Results: The lone operation group was significantly younger (51.3  10.5 vs 58.8
 9.9 years) and had a higher male/female ratio (4:1 vs 2:1). There was no
difference in operative mortality between groups (1.8% vs 1.2%). At a follow-up of
5.4 2.9 years, 96.6% (172/178) of all patients were free of atrial fibrillation. There
was no difference between the lone operation and concomitant procedure groups
(95.9% vs 97.5%).
Conclusion: The Cox maze III procedure has equivalent operative risk and long-
term efficacy in patients undergoing both lone operations and concomitant proce-
dures. The Cox maze III procedure remains the standard against which alternative
procedures for atrial fibrillation must be judged.
In the United States more than 2.2 million persons are known to have atrialfibrillation (AF).1 This arrhythmia is particularly common in the elderly,with an incidence of 6% in patients older than 80 years.2 AF causessignificant morbidity as a result of hemodynamic compromise, tachycardia-induced cardiomyopathy, and thromboembolic events. Stroke remains themost feared complication, with an overall incidence of 5% per year.3 This
is 2 to 7 times the risk of the general population without AF.4 In addition, a
staggering 24% of strokes in patients older than 80 years are due to AF.1 The
seriousness of this arrhythmia is evidenced by the fact that the mortality of patients
with AF is twice that of patients with normal sinus rhythm.5 Because of the
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significantly increased morbidity and mortality associated
with this disease, there have been aggressive attempts to
find a cure over the last several decades. Medical therapy,
transvenous ablation, and surgical intervention all play a
role in the modern treatment of AF.
The first Cox maze III procedure was performed in 1988.
The operation is based on the theory that AF results from
multiple macroreentry circuits in the atria. The operation
creates a maze-like series of incisions in both atria to
prevent the formation of these macroreentrant circuits. Dur-
ing the operation, the pulmonary veins are completely iso-
lated, and both appendages are removed.6,7 This was fortu-
itous because the importance of the pulmonary veins in the
initiation of AF has become more appreciated in recent
years.8 The procedure has been proved to be effective, with
a high success rate and elimination of late strokes.9
The present indications for a Cox maze III operation
include drug intolerance, arrhythmia intolerance, and recur-
rent embolic events. There are 2 major groups of patients
who are referred for this procedure: those with symptomatic
lone AF and those with AF associated with other organic
cardiac disease. It is likely that the underlying pathophysi-
ology responsible for the genesis of AF in these 2 groups of
patients is different. Thus one can expect differences in the
results of the Cox maze III procedure in these 2 populations.
This study examined the long-term efficacy of the Cox maze
procedure in patients undergoing the procedure either for
lone AF or as an adjunct to another major cardiac operation.
Methods
The full Cox maze III procedure was performed in all cases. In
each instance the patient underwent cardiopulmonary bypass and
cardioplegic arrest. Three surgeons at our institution performed all
operations (JC, TS, and RD). The majority of these procedures
(158) were performed by Dr James Cox. From January 1988 to
January 2002, 198 patients underwent a Cox maze III procedure
for AF. One hundred twelve patients had a lone procedure, and 86
patients had the operation performed as a concomitant procedure.
Follow-up and Data Analysis
The patients’ clinical profiles and perioperative outcomes were
recorded prospectively in a computerized database. Perioperative
complications were considered to be reoperation for bleeding,
renal failure requiring dialysis, mediastinitis, placement of an
intra-aortic balloon pump, perioperative transient ischemic acci-
dent or stroke, and perioperative myocardial infarction. Follow-up
was conducted by means of a mailed questionnaire or telephone
interview with the patient. A review of both the referring cardiol-
ogist’s office charts and recent electrocardiograms (ECGs) was
performed for any patient who stated that they were in AF or were
taking medication. Information on each patient who died during
the follow-up period was obtained from relatives, family physi-
cians, or county death certificates. Atrial tachyarrhythmias occur-
ring in the first 3 months were not counted.
All of the patients in this series had chronic AF, which was
defined as a documented duration of longer than 6 months. Par-
oxysmal AF was defined as patients who were intermittently in
AF. Persistent AF was defined as patients who were continuously
in AF. This study was approved by the Washington University
School of Medicine/Barnes-Jewish Hospital Institutional Review
Board. Informed consent and release of information was obtained
from each participant. The closing date for enrolling patient data
for this study was January 1, 2002. Thus all patients had a mini-
mum of 3 months’ follow-up. Late survival and outcomes were
recorded and analyzed according to Society of Thoracic Surgeons
database guidelines. Data were collected and managed in Mi-
crosoft Access 2000 and analyzed with SysStat version 10.0 soft-
ware (SPSS Corp, Chicago, Ill). The clinical profiles of the 2
groups of patients were compared by using the 2 test or the Fisher
exact test. Continuous variables, such as age, were compared with
the unpaired t test with a Dunn correction. Late survival and
time-dependant morbidity were evaluated univariately by means of
Kaplan-Meier analysis with the Mantel log-rank test and, a mul-
tivariate analysis was performed by using Cox regression.
Results
Patient Demographics
Lone maze procedure. The mean age of these patients
was 51.3 10.5 years (range, 20-77 years). There was a 4:1
ratio of men to women (90:22). There were 72 (64.3%)
patients with paroxysmal AF lasting for a mean of 8.5 7.5
years before the operation. Forty (35.7%) patients were
operated on for persistent AF, with a mean preoperative
duration of 11.6  10.0 years.
In this group the indication for arrhythmia surgery was
19 (17%) of 112 patients with documented cerebral vascular
accidents, 5 (4%) patients with medication intolerance, and
the majority of patients (88 [79%]) with arrhythmia
intolerance.
Concomitant maze procedure. The Cox maze procedure
was performed as a concomitant procedure at our institution
starting in April 1992. The most common concomitant
procedures were mitral repair, mitral valve replacement, and
coronary artery bypass grafting (Table 1). The mean age of
patients in this group was 58.8  9.9 years (range, 25-75
TABLE 1. Concomitant procedures (n  86)
Mitral valve repair/replacement 26
Mitral valve procedure  CABG 9
Mitral valve procedure  TVR 2
Mitral valve procedure  AVR 1
Mitral valve repair  ASD 1
CABG  AVR 1
CABG 31




CABG, Coronary artery bypass grafting; TVR, tricuspid valve repair; AVR,
aortic valve replacement; ASD, closure of atrial septal defect.
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years), which was significantly higher than that in the lone
operation group (P  .01, Table 2). In this group the
indications for the procedure included documented cerebral
vascular event (19/86 [22%]), failed medications (2/86
[2%]), and arrhythmia intolerance (65/86 [76%]). There was
an approximately 2:1 ratio in favor of men (53:33), which
was a significantly smaller ratio than in the lone operation
group (P  .01). There were 45 (52.3%) patients with
persistent AF and 41 (47.7%) with paroxysmal AF. The
mean length of AF in the persistent AF group was 5.4 4.9
years, and in the paroxysmal AF group it was 6.3  5.1
years.
Perioperative Results
Lone maze procedure. The average aortic crossclamp
time was 93  34 minutes, with a mean cardiopulmonary
bypass time of 163  35 minutes. The median intensive
care unit (ICU) stay was 2 days (range, 1-50 days), and the
median total length of stay was 9 days (range, 4-50 days).
There were 2 (1.8%) perioperative deaths among 112 pa-
tients. One patient dies on postoperative day 28 from mul-
tiorgan system failure caused by delayed tamponade. The
second patient died from acute respiratory failure caused by
aminodarone toxicity on postoperative day 8.
There were 12 (10.7%) major complications: 3 (2.7%)
reoperations for bleeding, 2 (1.8%) patients with renal fail-
ure, 4 (3.6%) patients with intra-aortic balloon pump place-
ment, and 1 (0.9%) patient with mediastinitis. There were 2
(1.8%) perioperative strokes/transient ischemic accidents.
There were no documented postoperative myocardial in-
farctions. A total of 9 (8.0%) patients required placement of
a pacemaker postoperatively. Six (67%) patients who re-
ceived postoperative pacemakers had been given a diagno-
sis of sick sinus syndrome preoperatively. The incidence of
postoperative pacemaker placement with normal preopera-
tive sinus node function was 3% (3/106).
Concomitant maze procedure. The mean cardiopulmo-
nary bypass time in this group was 201  42 minutes, with
an average crossclamp time of 123  35 minutes. The
median ICU stay was 3 days (range, 1-78 days). The median
total length of stay was 12 days (range, 5-78 days). There
was 1 (1.2%) perioperative death among 86 patients. This
patient died from respiratory failure caused by adult respi-
ratory distress syndrome on postoperative day 22. There
were 12 (13.9%) perioperative complications: 6 (7.0%) pa-
tients returned to the operating room for bleeding, 1 (1.2%)
patient had renal failure, 3 (3.5%) patients required the
placement of an intra-aortic balloon pump, and 1 (1.2%)
patient had mediastinitis. There was 1 (1.2%) patient with a
stroke. None of the patients had a postoperative myocardial
infarction. Twenty (23.3%) of these patients required post-
operative pacemakers (Table 3).
The most significant differences between the 2 groups
were age, sex, pump time, and crossclamp time (Table 3).
The lone operation group was younger by almost 7 years,
and there was a greater proportion of male patients in this
group. Obviously the pump and crossclamp times in the
concomitant procedure group were longer because of the
concomitant procedures. The ICU time and length of stay
were both longer in the concomitant procedure group, most
likely because of the significantly longer crossclamp and
pump times. There was no difference in operative mortality
between the groups despite the differences in their demo-
graphics. Interestingly, the patients with lone AF had a
significantly smaller chance of receiving a pacemaker post-
operatively. This is intriguing because the duration of pre-
operative AF was longer in this group. The majority of the
pacemakers placed after a concomitant procedure were the
result of bradycardia, and 9 (45%) of the 20 patients had the
preoperative diagnosis of sick sinus syndrome. The inci-
dence of postoperative pacemaker placement in patients
with normal sinus node function preoperatively in both






Age (y) 51.3 10.5 58.8 9.9 .001
Sex (M:F) 90:22 53:33 .003
PAF:PTAF 72:40 45:41 .08
Pump time (min) 162 35 201 42 .001
Crossclamp time (min) 93 34 122 37 .001
Mortality 2/112, 1.8% 1/86, 1.2% .99
Median ICU stay (d) 2 3 .007
Median LOS (d) 9 12 .01
PAF, Paroxysmal atrial fibrillation; PTAF, persistent atrial fibrillation; LOS,
length of stay.








3/112, 2.7% 6/86, 7.0% .18
Renal failure 2/112, 1.8% 1/86, 1.2% .99
Intra-aortic
balloon pump
4/112, 3.8% 3/86, 3.5% .99
Mediastinitis 1/112, 0.9% 1/86, 1.2% .99
Stroke 2/112, 1.8% 1/86, 1.2% .99
Postoperative
pacemaker
9/112, 8.0% 20/86, 23.3% .004
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groups (lone operation plus concomitant procedure) was
7.7% (14/183).
Late Follow-up
There was no significant difference between the groups in
mean duration of follow-up or percentage of patients lost to
follow-up. The mean duration of follow up was 5.4  3.0
and 5.4  2.7 years in the lone operation and concomitant
procedure groups, respectively. Late follow-up was
achieved in 98 (87.5%) of 112 patients in the lone operation
group and in 79 (91.9%) of 86 patients in the concomitant
group.
Patient survival. In the lone Maze procedure there were
3 (3.1%) late deaths in the lone operation group among 98
patients. All patients were free of AF. In the concomitant
procedure group there were 7 (8.9%) late deaths, and all
patients were free of AF before death. Six patients died as
a result of a noncardiac cause, such as cancer, ischemic
colitis, and late renal failure. One patient died of chronic
heart failure. Information on the other 3 patients is currently
unavailable.
Thromboembolic events. There was only one late stroke
in the entire series, and this was in the lone operation group.
This patient had a cerebrovascular accident to the right
temporal lobe with residual symptoms of hoarseness, loss of
fine motor abilities, and difficulty concentrating.
Warfarin sodium. All patients discharged after a Cox
maze III procedure were prescribed warfarin sodium (Cou-
madin) for 3 months. In the lone operation group the ma-
jority of our patients were referrals from other states (95/
112 [84.8%]). After their postoperative clinic visit, their
medications were managed by their cardiologists or family
physicians. In our study 12 (12.2%) of the 98 responders
were taking warfarin at late follow-up.
Similar to the lone operation group, the majority of
patients were out of state in the concomitant procedure
group (66/86 [76.7%]). In this study 18 (20.9%) of the 86
responders were taking warfarin. Eleven (61.1%) of these
18 required anticoagulation for their prosthetic valve. The
overall use of warfarin, excluding these patients, was 9.3%
(7/75).
Recurrence of AF. In the lone maze procedure group all
patients who identified themselves as being in AF were
considered failures unless their cardiologist and an ECG or
Holter recording documented otherwise. Only 4 (4.1%) of
98 patients in the lone operation group were in AF at
follow-up. Seventy-eight (79.6%) patients were not in AF
and free of antiarrhythmic medications. Sixteen (16.3%)
patients were in normal sinus rhythm but were taking anti-
arrhythmic drugs.
In the concomitant maze procedure group, of the 79
responders, 2 (2.5%) patients were in AF. Fifty-eight
(73.4%) patients were in sinus rhythm and off all antiar-
rhythmic medication. An additional 19 (24%) patients were
free of AF but were taking medications. There was no differ-
ence in freedom from AF between the 2 groups (Figure 1).
Overall, the Kaplan-Meier estimate for freedom from AF
for patients in the lone operation group at 14 years is 92%.
The concomitant procedure had a freedom from AF of 97%
at 10 years. Statistically time matched at 10 years, there was
no difference in freedom from AF between the 2 groups (P
 .64). There also was no statistical difference in late
freedom from AF when comparing patients with persistent
versus paroxysmal AF.
Discussion
This is the first study to compare the long-term efficacy of
the Cox maze III procedure either as a lone operation or as
Figure 1. Kaplan-Meier survival analysis of freedom from recurrent AF. The numbers on each line indicate the
number of patients at risk. There was no difference in the long-term estimate of freedom from AF between the lone
maze group (L) and the concomitant group (C; P  .64).
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an adjunct to another major cardiac procedure. Supporting
our initial hypothesis, there were significant differences
between the 2 patient populations. The lone operation group
had a higher population of patients with paroxysmal AF
than the concomitant procedure group (P  .08). The lone
operation group was significantly younger, was more likely
to be male, and had shorter cardiopulmonary bypass times.
Postoperatively, the lone operation group, as would be
expected, had shorter ICU and postoperative stays. The
incidence of postoperative pacemaker placement was less in
the lone operation group.
In this study this procedure had excellent results in
curing AF in both groups. Despite the longer crossclamp
and cardiopulmonary bypass times, there was no difference
in the morbidity and mortality between these 2 populations.
The incidence of postoperative complications was identical
between groups, except for a trend toward more reopera-
tions for bleeding in the concomitant procedure group. Late
complications were rare in both groups. It was noteworthy
that there was only one late stroke reported in both groups.
The Cox maze III procedure reduced the risk of stroke in
this high-risk population. The incidence of stroke in patients
with AF has been reported by the American Heart Associ-
ation and the American College of Cardiology to be 5% per
year, and even with anticoagulation, the risk is 2% to 3%
per year.10 One of the greatest benefits of this procedure was
the reduction of stroke as a late complication at a follow-up
period of 5.4  2.9 years. Moreover, the majority of pa-
tients (148/178 [83.1%]) were able to discontinue warfarin,
which carries its own long-term risk of morbidity. In pa-
tients without prosthetic valves, only 9% still required an-
ticoagulation.
The overall freedom from AF at follow-up was 97%. The
great majority of these patients also had stopped taking both
antiarrhythmic drugs and warfarin. With a high long-term
cure rate and the benefits of being able to stop all medica-
tions, why is the Cox maze procedure so seldom performed
in patients with refractory AF?
First, the procedure has been viewed as invasive and
entailing significant morbidity because of the prolonged
period of cardiopulmonary bypass required to perform the
operation. However, a close examination of the alternatives
for many patients clearly favors a more aggressive surgical
approach. In patients with lone AF, the arrhythmia itself,
antiarrhythmic drugs, and anticoagulation all have well-
documented and significant complications.11 This study
demonstrated that the Cox maze III procedure has a low
mortality in this population (2/112 [1.8%]) while offering
the patient a greater than 95% chance of a cure, reducing the
risk of stroke.
In patients who have preoperative AF and are undergo-
ing primary cardiac surgery for other reasons, these data
suggest that selected patients would benefit from a Cox
maze III procedure. The mortality of the concomitant pro-
cedure was low (1/86 [1.2%]), which compares favorably
with the national average for coronary and mitral valve
surgery.12 At our institution, our comparative mortality over
a similar time period for elective coronary artery bypass
grafting was 2.6% and for mitral valve repair was 2.4%.
Although the addition of the Cox maze III procedure did not
increase perioperative mortality, it did lengthen hospital
stay (median, 12 days). However, the long-term benefits of
this procedure in preventing stroke and eliminating the need
for anticoagulation, particularly in patients undergoing mi-
tral valve repair, would appear to outweigh this short-term
inconvenience.
The long-term success rates in these patients would ar-
gue strongly for a more widespread adoption of the Cox
maze procedure. The success of this procedure in the con-
comitant procedure group might be due to the correction of
physiologic abnormalities, such as ischemia or left atrial
distension, which could predispose a patient to AF. Our
results are supported by other studies that have reported the
efficacy of the Cox maze III procedure in patients undergo-
ing mitral valve surgery.13-15
In this series 15% (29/198) of patients required a post-
operative pacemaker. This has been used by some physi-
cians as a reason to discourage the wider use of this oper-
ation. However, it is instructive to closely look at this group
of patients. First of all, there was a significant difference in
postoperative pacemaker placement between the 2 groups,
8% in the lone operation group versus 23% in the concom-
itant procedure group. Second, many of these patients were
given a preoperative diagnosis of sick sinus syndrome. In
patients with normal preoperative sinus node function, our
rate of pacemaker placement was only 8% (14/183 [7.7%]).
Left atrial dysfunction has been reported as a common
late sequelae of the Cox maze III procedure, occurring as a
result of the extensive surgical manipulation of the left
atrium.16 In this study left atrial function was not quantified.
Regardless of the precise incidence of left atrial dysfunc-
tion, our data would suggest that if it occurs, it is not of
physiologic significance. The great majority of our patients
(148/178 [83.1%]) were not receiving anticoagulation. If
there had been a physiologically significant reduction in left
atrial function, especially in a study that spanned 14 years,
one would have expected a higher rate of stroke, mortality,
or both caused by heart failure. Neither of these problems
was observed in this patient population.
Another reason the procedure has not had widespread
adoption is the impression that the long-term efficacy is not
sufficient to warrant the risk. This study clearly supports the
success of this procedure in both groups of patients for the
treatment of paroxysmal and persistent AF. This miscon-
ception might be the result of many published reports that
inappropriately use the term “Cox maze” or “maze” proce-
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dure. Many of these studies use a different lesion set and are
based on the empiric elimination of one or more incisions to
simplify the procedure.17 These “maze” procedures have
had mixed results with short-term or immediate follow-
up.18,19 Moreover, the inappropriate use of the term “cath-
eter maze” by electrophysiologists has further confused the
issue. The catheter-based procedures have not been able to
fully replicate the entire set of surgical lesions described in
the classic Cox maze III procedure. Any procedure less than
a complete Cox maze III procedure must be considered a
new operation for AF and be carefully evaluated as such
both experimentally and clinically.
In summary, the Cox maze III procedure is effective in
curing AF in the majority of patients for whom nonsurgical
therapy has failed. The Cox maze III procedure is effica-
cious in patients with lone AF and should be offered to a
larger population of symptomatic patients. In patients un-
dergoing coronary or valve surgery, the Cox maze III pro-
cedure is successful in curing AF in virtually all patients and
did not add significantly to the expected mortality or mor-
bidity of this group of patients. These data support a policy
of offering a curative Cox maze III procedure to patients
with refractory AF undergoing open cardiac surgery.
The major strength of our study was the large number of
patients and the high percentage and duration of the follow-
up. The major limitation of this study was that it might have
underestimated the failure rate. Electrocardiographic fol-
low-up was not obtained on patients who stated that they
were in normal sinus rhythm and had stopped all medica-
tions. However, our follow-up of all patients who identified
themselves as having any atrial dysarrhythmia should have
captured the majority of treatment failures. Another limita-
tion of any long-term AF study is the possibility that the
patient might have had asymptomatic episodes of AF. Our
follow-up in many patients was only annual physician visit
ECGs, and this might have missed asymptomatic intermit-
tent rare episodes of AF. Unfortunately, the logistics of
continuously monitoring patients for years is not possible. If
patients were indeed in intermittent AF, one would have
expected a higher incidence of late strokes.
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Discussion
Dr Hartzell V. Schaff (Rochester, Minn). I agree with your
conclusion that the Cox maze operation is the gold standard
against which alternative procedures for AF must be judged. In
your clinical review you found a similarly low operative risk for
patients who had only the maze procedure compared with patients
who had concomitant cardiac surgery, and furthermore, you con-
clude that the late freedom from AF was similar in these groups.
Because this report will be widely quoted in the future and the
results compared with outcomes of new procedures and devices, I
think it is important to clarify a few issues and expand on 2 points.
First is the issue of patient selection and the generalizability of
your results to other practices. In this series of operations for AF,
concomitant operations were performed in 43% of patients. In our
experience with more than 400 maze operations, more than 80% of
patients have had valve repair or replacement, and therefore the
issue of incremental risk and long-term efficacy is important. And
although you found little difference in operative mortality between
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